JP2009544614A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009544614A5 JP2009544614A5 JP2009520846A JP2009520846A JP2009544614A5 JP 2009544614 A5 JP2009544614 A5 JP 2009544614A5 JP 2009520846 A JP2009520846 A JP 2009520846A JP 2009520846 A JP2009520846 A JP 2009520846A JP 2009544614 A5 JP2009544614 A5 JP 2009544614A5
- Authority
- JP
- Japan
- Prior art keywords
- immunogenic composition
- herv
- composition
- polypeptide
- individual
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 40
- 241000713887 Human endogenous retrovirus Species 0.000 claims description 36
- 230000002163 immunogen Effects 0.000 claims description 31
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 24
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 19
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 17
- 229920001184 polypeptide Polymers 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 13
- 230000004044 response Effects 0.000 claims description 10
- 241000700605 Viruses Species 0.000 claims description 8
- 230000001717 pathogenic effect Effects 0.000 claims description 8
- 210000004027 cell Anatomy 0.000 claims description 7
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 5
- 102000039446 nucleic acids Human genes 0.000 claims description 5
- 108020004707 nucleic acids Proteins 0.000 claims description 5
- 150000007523 nucleic acids Chemical class 0.000 claims description 5
- 230000005867 T cell response Effects 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 4
- 210000004400 mucous membrane Anatomy 0.000 claims description 4
- 238000007911 parenteral administration Methods 0.000 claims description 4
- 239000013598 vector Substances 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 3
- 239000002773 nucleotide Substances 0.000 claims description 3
- 125000003729 nucleotide group Chemical group 0.000 claims description 3
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 2
- 239000000427 antigen Substances 0.000 claims description 2
- 102000036639 antigens Human genes 0.000 claims description 2
- 108091007433 antigens Proteins 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 229940035032 monophosphoryl lipid a Drugs 0.000 claims description 2
- 239000013603 viral vector Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000001177 retroviral effect Effects 0.000 claims 1
- 230000028993 immune response Effects 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83246506P | 2006-07-21 | 2006-07-21 | |
| PCT/US2007/016403 WO2008011120A2 (en) | 2006-07-21 | 2007-07-19 | Human endogenous retrovirus polypeptide compositions and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009544614A JP2009544614A (ja) | 2009-12-17 |
| JP2009544614A5 true JP2009544614A5 (enExample) | 2010-09-02 |
Family
ID=38957380
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009520846A Pending JP2009544614A (ja) | 2006-07-21 | 2007-07-19 | ヒト内在性レトロウイルスポリペプチド組成物およびその使用法 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20080171061A1 (enExample) |
| EP (1) | EP2046380A4 (enExample) |
| JP (1) | JP2009544614A (enExample) |
| KR (1) | KR20090060410A (enExample) |
| CN (1) | CN101557823A (enExample) |
| AU (1) | AU2007275693A1 (enExample) |
| BR (1) | BRPI0714714A2 (enExample) |
| CA (1) | CA2658393A1 (enExample) |
| IL (1) | IL196516A0 (enExample) |
| MX (1) | MX2009000659A (enExample) |
| NO (1) | NO20090818L (enExample) |
| RU (1) | RU2009106089A (enExample) |
| SG (1) | SG173997A1 (enExample) |
| WO (1) | WO2008011120A2 (enExample) |
| ZA (1) | ZA200900379B (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE045482T2 (hu) | 2005-06-27 | 2019-12-30 | Glaxosmithkline Biologicals Sa | Immunogén készítmény |
| US20090297530A1 (en) * | 2006-05-22 | 2009-12-03 | Feng Wang-Johanning | Herv-k antigens, antibodies, and methods |
| EP2340851A4 (en) * | 2008-09-18 | 2012-09-26 | Univ Keio | DIAGNOSTIC METHOD AND THERAPEUTIC METHOD FOR CANCER |
| WO2010053772A2 (en) | 2008-10-29 | 2010-05-14 | The Regents Of The University Of California | Disease-associated antigens and methods of use thereof |
| EP2519539A4 (en) * | 2009-12-28 | 2013-11-13 | Ligocyte Pharmaceuticals Inc | METHODS FOR STABILIZING VIRUS-LIKE PARTICULATE SOLUTIONS BASED ON INFLUENZA-INFLUENZA-VIRUSED VIRUSES |
| US20120321637A1 (en) * | 2011-06-20 | 2012-12-20 | The Board Of Regents Of The University Of Texas System | Combination cancer therapy with herv inhibition |
| IL330095A (en) | 2012-01-26 | 2026-08-01 | Vanda Pharmaceuticals Inc | Tesimalta for use in the treatment of asynchronous circadian rhythm of cortisol |
| US11918557B2 (en) | 2012-01-26 | 2024-03-05 | Vanda Pharmaceuticals Inc. | Treatment of circadian rhythm disorders |
| US20160145348A1 (en) | 2013-03-14 | 2016-05-26 | Fred Hutchinson Cancer Research Center | Compositions and methods to modify cells for therapeutic objectives |
| US11090285B2 (en) | 2013-11-12 | 2021-08-17 | Vanda Pharmaceuticals Inc | Treatment of circadian rhythm disorders |
| US10376487B2 (en) | 2013-11-12 | 2019-08-13 | Vanda Pharmaceuticals Inc. | Method of treatment |
| EP4166161B1 (en) | 2016-04-14 | 2026-03-04 | Fred Hutchinson Cancer Center | Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers |
| JP7046016B2 (ja) | 2016-06-30 | 2022-04-01 | ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ | Ｈｅｒｖ－ｅ反応性ｔ細胞受容体および使用方法 |
| WO2018037042A1 (en) * | 2016-08-23 | 2018-03-01 | Aimvion A/S | Novel immunostimulating peptides |
| WO2018129270A1 (en) | 2017-01-05 | 2018-07-12 | Fred Hutchinson Cancer Research Center | Systems and methods to improve vaccine efficacy |
| EP3606550A2 (en) * | 2017-04-03 | 2020-02-12 | Neon Therapeutics, Inc. | Protein antigens and uses thereof |
| US11351247B2 (en) | 2017-09-01 | 2022-06-07 | Inprother Aps | Vaccine for use in the prophylaxis and/or treatment of a disease |
| TW201930340A (zh) | 2017-12-18 | 2019-08-01 | 美商尼恩醫療公司 | 新抗原及其用途 |
| WO2019143948A1 (en) | 2018-01-18 | 2019-07-25 | Fred Hutchinson Cancer Research Center | Altering inflammatory states of immune cells in vivo by modulating cellular activation states |
| SG11202012653XA (en) | 2018-06-19 | 2021-01-28 | Biontech Us Inc | Neoantigens and uses thereof |
| WO2020049169A1 (en) * | 2018-09-06 | 2020-03-12 | Centre Léon-Bérard | Herv-k-derived antigens as shared tumor antigens for anti-cancer vaccine |
| US20220259617A1 (en) | 2019-06-13 | 2022-08-18 | The General Hospital Corporation | Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells |
| BR112023001272A2 (pt) | 2020-07-24 | 2023-04-04 | Massachusetts Gen Hospital | Partículas semelhantes a vírus aprimoradas e métodos de uso das mesmas para entrega às células |
| WO2024108001A2 (en) * | 2022-11-16 | 2024-05-23 | The General Hospital Corporation | Minimal human-derived virus-like particles and methods of use thereof for delivery of biomolecules |
| US20260035415A1 (en) * | 2024-08-01 | 2026-02-05 | Twilight Bioscience, Inc. | Herv-k (hml-2) env analog fusion proteins for antigen specific immunotherapy and methods of use |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030092145A1 (en) * | 2000-08-24 | 2003-05-15 | Vic Jira | Viral vaccine composition, process, and methods of use |
| US20030162263A1 (en) * | 2001-09-06 | 2003-08-28 | Marc Dupuis | Peptides derived from the superantigen (SAg) ENV protein of HERV-K18 and their use in obtaining SAG-inhibitory antibodies and in vaccination against SAG |
| AT411262B (de) * | 2001-09-27 | 2003-11-25 | Wolff Klaus Dr | Humanes endogenes retrovirus |
| JP4822490B2 (ja) * | 2001-12-07 | 2011-11-24 | ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド | 腫瘍形成形質転換に関連する内因性レトロウイルスポリペプチド |
| US20040096457A1 (en) * | 2001-12-11 | 2004-05-20 | Huber Brigitte T | Treatment and prevention of ebv infection and ebv-associated disorders |
| EP1338606A1 (en) * | 2002-02-22 | 2003-08-27 | Magnus Von Knebel Doeberitz | Nucleic Acid encoding an HERV-H polypeptide for diagnosing colorectal cancer |
| US20130108653A1 (en) * | 2009-12-22 | 2013-05-02 | Shervin Bahrami | Bivalent molecules for hiv entry inhibition |
| US20120321637A1 (en) * | 2011-06-20 | 2012-12-20 | The Board Of Regents Of The University Of Texas System | Combination cancer therapy with herv inhibition |
-
2007
- 2007-07-19 CA CA002658393A patent/CA2658393A1/en not_active Abandoned
- 2007-07-19 SG SG2011052784A patent/SG173997A1/en unknown
- 2007-07-19 JP JP2009520846A patent/JP2009544614A/ja active Pending
- 2007-07-19 US US11/880,126 patent/US20080171061A1/en not_active Abandoned
- 2007-07-19 CN CNA2007800276077A patent/CN101557823A/zh active Pending
- 2007-07-19 AU AU2007275693A patent/AU2007275693A1/en not_active Abandoned
- 2007-07-19 RU RU2009106089/15A patent/RU2009106089A/ru not_active Application Discontinuation
- 2007-07-19 EP EP07836155.7A patent/EP2046380A4/en not_active Withdrawn
- 2007-07-19 BR BRPI0714714-7A patent/BRPI0714714A2/pt not_active IP Right Cessation
- 2007-07-19 MX MX2009000659A patent/MX2009000659A/es not_active Application Discontinuation
- 2007-07-19 KR KR1020097003239A patent/KR20090060410A/ko not_active Withdrawn
- 2007-07-19 ZA ZA200900379A patent/ZA200900379B/xx unknown
- 2007-07-19 WO PCT/US2007/016403 patent/WO2008011120A2/en not_active Ceased
-
2009
- 2009-01-14 IL IL196516A patent/IL196516A0/en unknown
- 2009-02-20 NO NO20090818A patent/NO20090818L/no not_active Application Discontinuation
-
2013
- 2013-05-10 US US13/891,970 patent/US20130323279A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2009106089A (ru) | Композиции, содержащие полипептид эндогенного ретровируса человека, и способы их применения | |
| TW202200199A (zh) | 冠狀病毒疫苗及使用方法 | |
| Ide et al. | Peptide‐loaded dendritic‐cell vaccination followed by treatment interruption for chronic HIV‐1 infection: a phase 1 trial | |
| JP2021001216A (ja) | インフルエンザ抗原送達用のベクターおよび構築体 | |
| EP3156068B1 (en) | Pharmaceutical compositions comprising a polypeptide comprising at least one cxxc motif and heterologous antigens and uses thereof | |
| Fifis et al. | Short peptide sequences containing MHC class I and/or class II epitopes linked to nano-beads induce strong immunity and inhibition of growth of antigen-specific tumour challenge in mice | |
| EP2247306B1 (en) | Immunogenic control of tumours and tumour cells | |
| JP6780852B2 (ja) | Ｂ型肝炎ウイルス感染に対する治療ワクチン接種のための合成長鎖ペプチド（ｓｌｐ） | |
| CN111533812B (zh) | 针对sars-cov-2病毒的dna疫苗及其用途 | |
| PT1035865E (pt) | Tat do hiv-1 ou respectivos derivados para vacinação profiláctica e terapêutica | |
| CN111565746A (zh) | 用于预防和治疗多种黄病毒的mhc i类相关肽 | |
| RU2011138160A (ru) | Пептиды foxmi и вакцины, содержащие их | |
| US20260124290A1 (en) | HIV Immunogens, Vaccines, and Methods Related Thereto | |
| US20220047695A1 (en) | Compositions comprising self-assembling vaccines and methods of using the same | |
| JP2025003964A (ja) | 抗癌ワクチンのための共有腫瘍抗原としてのｈｅｒｖ－ｋ由来抗原 | |
| JP2013523084A5 (enExample) | ||
| JP2011522777A5 (enExample) | ||
| Memarnejadian et al. | Fusion of HBsAg and prime/boosting augment Th1 and CTL responses to HCV polytope DNA vaccine | |
| US10869921B2 (en) | Compositions and methods to treat AIDS | |
| JP2014506114A5 (enExample) | ||
| JP2012526519A5 (enExample) | ||
| JP2010029217A (ja) | Ｈｉｖ特異的ｃｔｌを誘導し得るペプチド及び該ペプチドを含む抗ａｉｄｓ予防・治療剤 | |
| RU2011140168A (ru) | Пептиды vangl1 и содержащие их вакцины | |
| Chen et al. | Identification of SARS-COV spike protein-derived and HLA-A2-restricted human CTL epitopes by using a new muramyl dipeptide-derivative adjuvant | |
| Bongard et al. | Interference of retroviral envelope with vaccine-induced CD8+ T cell responses is relieved by co-administration of cytokine-encoding vectors |